with 255 unique sites was obtained. LV-ARSA exhibited a strong bias for integration in tandem repeats and near interspersed repeats (e.g. LINEs, SINEs and LTR elements) rather than integration in or near genes. Several genomic hotspots for LV-ARSA integration were identifi ed along with a strong consensus target site sequence motif, (TG) 9 GCXTG. Moreover, the analysis identifi ed non-B DNAforming motifs as a new factor that infl uences lentivirus integration site targeting. Further inspection of the integration sites revealed that 12 genomic positions in chromosomes 2, 3, 4, 8, 10, 15 and X hosted two or more independent integration events. Two different regions were highly favored, hosting 18% of the total integration events. One region was located on chromosome 4 in an intron of foxj3 and the second was located on chromosome 10 in an intron of stxbp5. Closer inspection of the target DNA sequence for these sites revealed that all 37 sites were located in or within 100 bases of a direct repeat sequence. Consistent with previous fi ndings with lentiviral vectors, LV-ARSA disfavored integration in or near transcription start sites. Furthermore, none of the LV-ARSA integration sites were located in or within 50 kb of known murine cancer-related genes. Together, this data contributes new knowledge of host factors that infl uence lentiviral integration targeting and adds to a body of evidence suggesting that lentiviral vectors are candidates for safe and effective intraventricular CNS gene therapy.
Effi cient Long Lasting AAV Gene Therapy in a Mouse Model of Crigler-Najjar Syndrome Type I: Coming of Age?
Luka Bockor, 1 Giulia Bortolussi, 1 Lorena Zentilin, 1 Giulia Chiaruttini, 1 Mauro Giacca, 1 Federica Benvenuti, 1 Andrés F. Muro. 1 1 International Centre for Genetic Engineering and Biotechnology (ICGEB) , Trieste, TS, Italy.
The Crigler-Najjar Type I Syndrome is a rare monogenic disease (incidence around 1/10ˆ6 births) caused by Uridine-diphosphateglucuronosyltransferase (UGT)1A1 enzyme deficiency, which is responsible for bilirubin conjugation in the liver. There is no permanent cure and hyperbilirubinemia is associated with lifelong risk of kernicterus, that produces serious neurological damage leading to death if untreated. At present, CNSI patients are temporarily treated with daily intensive phototherapy, severely affecting their social life. However, the effectiveness of phototherapy is reduced with the age. The only effective therapy is liver transplantation, feasible only in a restricted number of cases and associated with signifi cant morbidity and mortality. It requires lifelong immunosuppression and involves substantial risks and costs.
We aim to set up an effective and long lasting therapy for the defi nitive cure of the disease, based on the use of AAV vectors, that could promptly be translated to CNSI patients.
To this aim, we performed neonatal and adult transduction in a mouse model of Crigler-Najjar Type I Syndrome developed in our laboratory with AAV vectors carrying the hUGT1a1 cDNA under the control of a liver-specifi c promoter.
We fi rst tested the strength of different liver-specifi c promoters in vitro and in vivo, and showed that the alpha-1-antitrypsin promoter with the ApoE enhancer was the most effi cient one. A single i.p. neonatal injection (AAV8-AAT-hUGT1a1 at P4) resulted in a therapeutically signifi cant decrease of plasma bilirubin (~2.5 mg/dL at 13 months). We then performed i.p. neonatal injection (AAV8-AAT-hUGT1a1 at P4), followed by the i.v. injection of AAV9-AAT-hUGT1a1 at P60. This protocol proved to be more effi cient than a single neonatal injection, as plasma UCB levels were very close to wt (~1 mg/dL at 13 months after injection). A single adult injection (P60, iv injection) was even more effective, with plasma UCB reaching concentrations undistinguishable from wt levels even after 13 months. However, this procedure was effective only in males, as plasma UCB in females increased over time, reaching values similar to control mutant mice levels. We detected a humoral immune response against the transgene in females. The response was not dependent on the transduction and ectopic expression in APC, as the response was similar with constructs containing a miRNA142-sponge in sense or antisense orientation. miRNA 142 is specifi cally expressed in APC, and the presence of the sponge completely abolishes expression of the mRNA. Motor coordination abilities of all treated mice were normal. The presence of a cellular immune response will be assessed.
We conclude that neonatal injection in both genders and adult injection of males promote immunological tolerance to Ugt1a1 and results in a very effi cient long-term correction of the disease, while adult injection in females results in an immune response against the transgene with a failure to improve the hyperbilirubinemic condition. Crigler-Najjar syndrome type I (CNSI) is a rare genetic disorder characterized by the inability to conjugate bilirubin due to uridine diphospho-glucuronosyl transferase 1a1 (UGT1a1) defi ciency. As a consequence, babies have high levels of unconjugated bilirubin and are at constant risk of developing neurological damage unless phototherapy (PT) is applied since birth. However, during puberty PT becomes less effective, and liver transplantation is required.
Transduction with Codon Optimized hUGT1a1 AAV Vectors for More Effi cient Crigler-Najjar Syndrome Gene Therapy
To fi nd alternative therapies to permanently correct the genetic defect we generated a mouse model of CNSI that closely reproduce all major features of CNSI such as neonatal hyperbilirubinemia, extensive neuronal cell death, motor impairment and ultimately death.
So far, several AAV-based gene therapy approaches have been performed to correct the genetic defect in pre-clinical models of CNSI. Although very promising, none of them have been translated to the clinic. To this aim, we initiated a concerted study, both in our lethal mouse model and in the less severe Gunn rat model, to defi ne the best vector construct, to bring safety and effi cacy of the approach to patients.
A series of ssAAV vector constructs expressing the human UGT1A1 transgene under the transcriptional control of a liver-specifi c promoter were developed. The hUGT1A1 used was wild-type or Codon-Optimized (CO) with different algorithms. These vectors were prepared by the AAV production facility at the Genethon Institute, Evry, France. All constructs were encapsidated into the AAV8 serotype.
To more accurately determine the effi ciency of the vectors, we used the lethal mouse model of CNSI developed in our lab. FVB Ugt1a mutant mice at post-natal day 2 (P2) and P4 were transduced with high and low doses (3.3x1011 and 3.3x1010 vgp/animal) of the different constructs. All vectors and doses rescued the lethal phenotype. However, while plasma UCB levels (measured at P30) were in the same range when the pups were transduced with the high dose, the effi ciency of one of the CO hUGT1A1 transgenes appeared to be signifi cantly higher than the wt and the other CO constructs at the lower dose, showing lower plasma UCB levels. The fi nal determination of the effi cacy of each vector will be assessed after the determination of genome copy number (viral genomes/diploid genome) in the liver. Moreover, we observed that transduction effi ciency was higher at P4 compared to P2 and that TB values of CO were not statistically different from WT untreated littermates.
DIABETES, METABOLIC AND GENETIC DISEASES II
Preliminary data show that ssAAV vector expressing the Codon Optimized hUGT1A1 is the most effi cient in lowering TB levels in the mouse model of CNSI. Sanfi lippo Syndrome type B, referred to as Mucopolysaccharidoses IIIB (MPS IIIB), is an autosomal recessive lysosomal storage disease caused by defective production of the enzyme α-Nacetylglucosaminidase (NAGLU), and is characterized by retention and accumulation of heparan sulfate, a biologically important glycosaminoglycan, in virtually every cell of the body. This disease is defi ned by severe and complex central nervous system (CNS) pathology, including aberrant neuronal signaling and infl ammation. Over time, cellular function becomes increasingly impaired, leading to severe mental degeneration and ultimately premature death. Treatment options are limited by the need to overcome the bloodbrain barrier and gain successful entry to the CNS. Here, our goal is to assess the relative effectiveness of several adeno-associated virus vectors (AAV) administered directly into the CNS, for therapeutic utility in gene therapy based treatment of this disease. Using the MPS IIIB mouse model, we perform a comprehensive comparative study of transduction and distribution patterns of AAV-GFP serotypes -5, -8, -9 and -rh10 administered to neonatal animals, by two different CNS directed intracranial routes -intracranial six site (IC6) and thalamic. The serotype exhibiting the best treatment potential is defi ned by broadest distribution and transduction profi les. The cortex, hippocampus, thalamus and cerebellum were assessed in each animal. Of the two methods compared, intracranial six site administration of AAV resulted in the broadest distribution pattern regardless of serotype. Neurons were primarily transduced by all serotypes, while microglia were least transduced. Considerably fewer cells were transduced in the cerebellum, followed closely by the thalamus. Transduction profi les of AAV8 and AAV9 were comparable in the hippocampus of wild-type and MPS IIIB animals, although varied in other focal areas. Importantly, AAV8 overwhelmingly transduced more cells and cell types compared to any other serotype, both in the intracranial six site; as well as, thalamic methods. AAV8 also demonstrated substantial widespread distribution, distal from sites of injection, compared to any other serotype via the intracranial six site method, concomitant with increased GFP expression compared to other serotypes. Noteworthy, differential distribution and transduction profi les were observed in wild-type compared to MPS IIIB animals. Given its superior distribution and tropism capacity, this data suggests that AAV8 represents the best therapeutic gene transfer vector for the treatment of MPS IIIB via the intracranial six site method.
AAV8 is Preferential Candidate for Neonatal Gene Transfer in Murine MPS IIIB Model

Helper-Dependent Adenoviral Vectors for Liver-Directed Gene Therapy of Primary Hyperoxaluria Type 1
Raffaele Castello, 1 Roberta Borzone, 1 Pasquale Piccolo, 1 Patrizia Annunziata, 1 Nicola Brunetti-Pierri. 1,2 1 Telethon Institute of Genetics and Medicine, Naples, Italy; 2 Translational Medicine, Federico II University, Naples, Italy.
Primary hyperoxaluria type 1 (PH1) is an inborn error of liver metabolism due to deficiency of peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes conversion of glyoxylate to glycine. AGT defi ciency results in overproduction of oxalate which ultimately leads to end-stage renal disease. Combined liver/kidney transplantation is the only therapeutic strategy available to prevent disease progression. Gene therapy is an attractive alternative to provide a defi nitive cure for PH1. Towards this goal, we investigated helper-dependent adenoviral (HDAd) vectors for liver-directed gene therapy of PH1. We injected PH1 mice with an HDAd encoding the AGT under the control of a liverspecifi c promoter and observed long-term normalization of urinary oxalate excretion. Upon challenge with ethylene glycol, a precursor of oxalate, vector injected mice showed reduced increase of urinary oxalate compared to saline controls. We previously developed a minimally invasive method to improve the therapeutic index of HDAd based on balloon occlusion catheter to achieve preferential delivery of the vector to the liver (Brunetti-Pierri et al., 2012) . This method may permit the use of clinically relevant doses of HDAd in humans. Based on risk:benefi t assessment, PH1 is an attractive disease for clinical application of this method. Recessive dystrophic Epidermolysis Bullosa (RDEB), one of the most severe forms of EB, is an incurable and lethal genodermatosis characterized by reduced or no collagen type VII. Loss-of-function mutations in the COL7A1 gene in RDEB result in extensive mucocutaneous blistering, esophageal strictures, mutilating scars, life-threatening infections, and aggressive squamous cell carcinomas. There is no treatment for RDEB, and an obvious question is how collagen VII can be provided to skin continuously? Ex vivo gene therapy has been considered an alternative using patient cells modifi ed genetically to produced collagen VII . Our propose in this project is to use the genetically corrected hematopoietic stem cells and/or macrophages with COL7A1 gene under the control of macrophage specifi c promoter -the promotor of Scavenger receptor. Thinking about a clinical protocol, non-viral integrative Sleeping Beauty System has been used to integrate the COL7A1 gene, which is safer than viral systems. Our expectative is that the collagen VII gene be expressed mainly in the skin because the chronically infl ammation could recruit the genetically modified macrophages. Initially, nucleofection was tested in hematopoietic stem cells and primary mouse macrophages (PMM). For in vivo assay, we had high and enough collagen VII expression only with PMM and HEK293, which was seen using the plasmid pT2-SP-Col7 containing human collagen VII gene and SP synthetic promoter of Scavenger receptor.
Macrophages Transplantation in RDEB
Next, we nucleofected PMM with pT2-SP-Col7 and pCMV-SB100X (expresses transposase SB) and labeled with Dil, and injected intradermally and intraperitoneally in neonatal RDEB mouse. The treated mice had prolonged life span and quality. The injected cells could be located in the skin and the human collagen VII was found in basal membrane and extracellular matrix. In mice injected with macrophages intraperitoneally, the human collagen VII expression and macrophages were seen in spleen, intestine and skin.
